New research indicates that patients who discontinue new weight-loss injections like Mounjaro or Wegovy tend to recover shed pounds far faster than those who halt conventional lifestyle regimens.
Published data in a leading medical journal demonstrates that while obese individuals can lose about a fifth of their body weight while on the medication, the mass comes back at an average rate of 0.8 kg per month once they quit.
"People using such treatments must be aware of the risk of rapid rebound weight gain when the treatment is stopped," stated expert Dr. Susan Jebb.
This pace of recovery suggests a reversion to original weight in about one and a half years.
Comparing Approaches
The analysis, which looked at 37 of trials involving over 9,000 of patients, compared the outcomes of the injectable medications with older methods.
The team note that individuals who shed pounds through lifestyle changes alone usually have a slower creep back—perhaps 100 grams monthly—once they finish.
The Reason for the Rapid Rebound
Nutrition scientists believe the mode of action of the drugs explains the accelerated regain.
The injections imitate a body's own chemical called GLP-1, which controls appetite.
"Long-term administration of GLP-1 levels far above than the body's typical production could lead to the body to produce less of its own natural GLP-1, and could lessen sensitivity to its actions," explained Dr. Adam Collins, a nutrition expert.
"Discontinuation of this hormone supplement results in appetite is unsuppressed, making overeating much more probable."
A Lifelong Condition?
The NHS advise the jabs for people with obesity-related health risks, alongside prescribed diet and exercise modifications.
A number of clinicians argue that, considering the likelihood of weight regain, the treatment is often life-long.
This opinion is reinforced by drug manufacturers, who note that the findings "underscore the persistent nature of excess weight," similar to managing conditions like hypertension.
User Accounts
Users who have stopped the jabs explain a sudden resurgence of appetite.
"I experienced something that goes on and I was suddenly starving," recalled a patient.
This difficulty is compounded if patients have not established lasting lifestyle or habit modifications during therapy.
Widespread Use
Survey data show that millions of people in the UK have used weight-loss jabs in the last 12 months, with interest being substantial.
- Adoption is more common among females than men.
- The middle-aged demographic shows the greatest level of interest.
- Many access the medications through private prescriptions rather than public health services.
In conclusion, experts caution that while these medications are powerful agents for weight loss, they are not a permanent fix and lasting health benefits hinges on integrated behavioural changes.
